Sweden's Cereno Scientific Q1 net loss widens amid clinical development

Cereno Scientific AB

27/05/2026 07:14

Overview
Sweden biotech firm reported no Q1 net sales and a wider net loss yr/yr
Company advanced CS1 and CS014 clinical programs, including regulatory approval for Phase I study
Cereno announced new collaboration with patient group and plans for CS585 preclinical studies

Outlook
Company expects first patient in global CS1 Phase IIb trial in PAH in June 2026
Cereno Scientific sees topline results from CS014 PK bridging study in mid-2026
Company plans APS-focused preclinical studies for CS585 to start in H1 2026

Result Drivers
PIPELINE DEVELOPMENT - Co said results reflect continued investment in advancing CS1 and CS014 clinical programs, including regulatory approvals and trial preparations

Company press release: ID:nMFN5Rscfm

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Adjusted EPS
 
-SEK 0.09
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Cereno Scientific AB is SEK17.80, about 218.1% above its May 26 closing price of SEK5.60

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)